Patient, 19-year-old male, presented with fever, abdominal pain, headache, and vomiting presented after vaccination with ChAdOx1 CoV-19 (AstraZeneca, University of Oxford, and Serum Institute of India, and adenoviral-based vaccine) with alteration in sensorium and thrombocytopenia. He was diagnosed to have extensive venous sinus thrombosis with mass effect, midline shift, and underwent decompressive hemicraniotomy. He had a good outcome.
ChanB, OdutayoA, JüniP, . Risk of vaccine-induced thrombotic thrombocytopenia (VITT) following the AstraZeneca/COVISHIELD adenovirus vector COVID-19 vaccines. Science Briefs of the Ontario COVID-19 Science Advisory Table. 2021;2(28). doi:10.47326/ocsat.2021.02.28.1.0A.
2.
PerryRJ, TamborskaA, SinghB, . Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet. 2021;398(10306):1147–1156.
3.
GreinacherA, ThieleT, WarkentinTE, WeisserK, KyrlePA, EichingerS.Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101.
4.
SchultzNH, SørvollIH, MichelsenAE, . Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124–2130.
5.
CukerA, GimottyPA, CrowtherMA, WarkentinTE.Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120(20):4160–4167.
